Company: GlaxoSmithKline, GSK
Location: United Kingdom
Drug Type: Protein Biologic
Mechanism Type: Axon regeneration
Mechanism: Ozanezumab (GSK 1223249) is a neurite outgrowth inhibitor (NOGO-A) monoclonal antibody. The rationale for testing ozanezumab in ALS is supported by evidence that NOGO is overexpressed in skeletal muscle of ALS patients, and inhibiting its expression may promote axonal sprouting of new neurites.
U.S. Status for ALS: Discontinued
 Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Meininger, V et al. Lancet Neurol. 2017 Mar;16(3):208-216.
 Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis. ClinicalTrials.gov, 9 Jul 2015. Accessed 9 Mar 2016 from https://clinicaltrials.gov/ct2/show/NCT01753076.
Last updated June 21st, 2017